bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIAF bioAffinity Technologies, Inc.

Closed 04-27 16:00:00 EDT

2.21

-0.02

-0.90%

盘后2.13

-0.08-3.62%

19:50 EDT

High2.23	Low2.02	Vol220.28K
Open2.20	D1 Closing2.23	Amplitude9.42%
Mkt Cap9.94M	Tradable Cap7.52M	Total Shares4.50M
T/O470.53K	T/O Rate6.48%	Tradable Shares3.40M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIAF","market":"US","secType":"STK","nameCN":"bioAffinity Technologies, Inc.","latestPrice":2.21,"timestamp":1777320000000,"preClose":2.23,"halted":0,"volume":220275,"hourTrading":{"tag":"盘后","latestPrice":2.13,"preClose":2.21,"latestTime":"19:50 EDT","volume":757,"amount":1609.7097,"timestamp":1777333838775,"change":-0.08,"changeRate":-0.036199,"amplitude":0.040045},"delay":0,"changeRate":-0.00896860986547086,"floatShares":3401400,"shares":4498700,"eps":-8.663011,"marketStatus":"Closed","change":-0.02,"latestTime":"04-27 16:00:00 EDT","open":2.2,"high":2.23,"low":2.02,"amount":470531.40997499996,"amplitude":0.09417,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.663011,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777363200000},"marketStatusCode":5,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":2.23,"preHourTrading":{"tag":"盘前","latestPrice":2.27,"preClose":2.23,"latestTime":"09:28 EDT","volume":3216,"amount":7185.1627584,"timestamp":1777296531257,"change":0.04,"changeRate":0.017937,"amplitude":0.040359},"postHourTrading":{"tag":"盘后","latestPrice":2.13,"preClose":2.21,"latestTime":"19:50 EDT","volume":757,"amount":1609.7097,"timestamp":1777333838775,"change":-0.08,"changeRate":-0.036199,"amplitude":0.040045},"volumeRatio":1.024829},"requestUrl":"/m/hq/s/BIAF/wiki","defaultTab":"wiki","newsList":[{"id":"2627445570","title":"bioAffinity releases case study on CyPath Lung test guiding nodule follow-up imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445570","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445570?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:01","pubTimestamp":1776168094,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies released a new clinical case study on CyPath Lung, its noninvasive sputum-based lung cancer diagnostic.Results have already been presented in the case study release.CyPath Lung delivered a negative result that supported a physician decision to order follow-up imaging instead of proceeding directly to biopsy.Subsequent imaging showed the suspicious lung finding had resolved, supporting an inflammatory explanation rather than cancer.Management framed CyPath Lung as a decision-support tool that can help defer unnecessary invasive procedures in high-risk patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL8xQnMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930595","title":"bioAffinity to present CyPath Lung test at Cleveland Clinic early lung cancer symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930595","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930595?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:01","pubTimestamp":1775563300,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies to present CyPath Lung at Cleveland Clinic “Advances in Early Lung Cancer Detection” symposium on April 16, 2026, in Cleveland, Ohio.Chief Medical Officer Gordon Downie to join panel on lung nodule management, highlighting CyPath Lung use in high-risk patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on April 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL81Mj0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624001513","title":"BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2624001513","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624001513?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:15","pubTimestamp":1775045744,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) announced that unit sales for its CyPath Lung diagnostic in the first quarter of 2026 exceeded internal projections...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinitys-cypath-lung-test-unit-sales-surged-146-y-y-in-q1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinitys-cypath-lung-test-unit-sales-surged-146-y-y-in-q1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624513351","title":"bioAffinity CyPath Lung unit sales jump 146% in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624513351?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:02","pubTimestamp":1775044964,"startTime":"0","endTime":"0","summary":"bioAffinity posted 146% year-over-year growth in Q1 2026 unit sales for CyPath Lung, based on preliminary unaudited data.US addressable market for pulmonary nodule management and lung cancer survivor surveillance was estimated at USD 3.58 billion.Projected US indeterminate pulmonary nodule volume was forecast to rise 62% to 4.7 million by 2030 from 2.9 million in 2025.Estimated lung cancer survivor population was projected to increase to more than 871,000 by 2030 from 680,000.CyPath Lung revenue rose 87% in 2025; test units sold increased 99% versus 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5nzSmF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077464","title":"What's Going On With bioAffinity Technologies Stock Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077464","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077464?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:51","pubTimestamp":1774450260,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc  shares are trading higher on Wednesday. The move follows an announcement regarding a new clinical education initiative.The company plans to host a live virtual physician roundtable on April 8. This event kicks off the “CyPath Lung in Practice” webinar series.A panel of pulmonologists will discuss integrating the noninvasive CyPath Lung test into clinical practice. They will share real-world patient cases.The focus remains on diagnosing indeterminate pulmonary nodules with greater certainty.Participating physicians will demonstrate how the test guides clinical paths. Cases include identifying Stage 1A lung cancer.The test also helps prevent “unnecessary invasive, risky and costly procedures,” according to the company. This occurs when CyPath Lung returns an “Unlikely” malignancy result.The news builds on recent growth. In 2025, CyPath Lung revenue rose 87% year-over-year. The number of tests performed jumped 99%. Management is currently moving away from low","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/25/The-Growth-Of-Prediction-Markets.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/25/The-Growth-Of-Prediction-Markets.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51458941/whats-going-on-with-bioaffinity-technologies-stock-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51458941/whats-going-on-with-bioaffinity-technologies-stock-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4217","SMA","BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622307369","title":"bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion","url":"https://stock-news.laohu8.com/highlight/detail?id=2622307369","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622307369?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:02","pubTimestamp":1774440176,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion. bioAffinity Technologies will host a live Zoom webinar, “CyPath Lung in Practice: A Physician Roundtable Discussion,” on Wednesday, April 8, 2026, at 7 p.m. ET/6 p.m. CT.Gordon Downie will moderate the session, with panelists Sai Karan Vamsi Guda, Michael Nicholson, and Gregory White.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on March 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4ZNcqh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620755504","title":"Why Is bioAffinity Technologies Stock Surging Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620755504","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620755504?lang=en_us&edition=fundamental","pubTime":"2026-03-17 22:32","pubTimestamp":1773757920,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) stock surges Tuesday after a new case study confirms CyPath Lung's role in noninvasive cancer diagnostics. Details here.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/17/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/17/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51298914/why-is-bioaffinity-technologies-stock-surging-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51298914/why-is-bioaffinity-technologies-stock-surging-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620313421","title":"bioAffinity Technologies releases CyPath Lung case study highlighting 92% sensitivity in nodules under 20 mm","url":"https://stock-news.laohu8.com/highlight/detail?id=2620313421","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620313421?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:45","pubTimestamp":1773747915,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies released a new clinical case study on its CyPath Lung noninvasive lung cancer test in a high-risk patient with multiple pulmonary nodules. The case study described a 71-year-old former smoker whose CyPath Lung result was “Unlikely Malignancy,” and the physician opted to wait for a follow-up CT scan rather than proceed to an invasive biopsy. A follow-up scan in October 2025 showed the suspicious nodules had resolved, while another small nodule remained unchanged. Separately, the company cited results from a clinical study that have already been presented, reporting 92% sensitivity and 87% specificity for detecting lung cancer in nodules smaller than 20 mm.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL8tshWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619114727","title":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114727?lang=en_us&edition=fundamental","pubTime":"2026-03-14 01:54","pubTimestamp":1773424469,"startTime":"0","endTime":"0","summary":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen BioWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL6N4010OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYIV","INDV","RJF","ESQ","IMM.AU","CVNY","CRCD","ARES","KLC","BW","CCUP","TVGN","AMPY","SANA","WDCX","IBG","PODD","CRVS","VACH","AMAT","FITB","BIAF","CVNA","AIFF","SDHC","CMCT","CVNX","ULTA","ICRC","HBAN","CRCO","DOUG","INMD","CRCA","ADBG","LVWR","VEON","SVCO","KLAR","ISPC","OFRM","PAR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619115310","title":"bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2619115310","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619115310?lang=en_us&edition=fundamental","pubTime":"2026-03-13 22:30","pubTimestamp":1773412200,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies shares are trading higher Friday after it reported FY25 results with strong growth in CyPath Lung diagnostic.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/13/Mystery-Rise-In-Otherwise-Healthy-Young-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/13/Mystery-Rise-In-Otherwise-Healthy-Young-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["RSI","BK4150","BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619194149","title":"bioAffinity Technologies FY2025 net loss widens 66% to USD 14.91 million on revenue down 34% to USD 6.16 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194149","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194149?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:02","pubTimestamp":1773403325,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies reported FY 2025 revenue of USD 6.16 million, down 34%, after discontinuing unprofitable pathology services and reallocating resources toward commercialization of its CyPath Lung test. FY 2025 net loss was USD 14.91 million. Operating expenses in FY 2025 fell 9% to USD 16.73 million. Testing revenue for CyPath Lung rose 87% and the number of tests performed increased 99%, while the number of ordering physician offices and clinics increased 67%. For FY 2026, bioAffinity forecast CyPath Lung unit sales to more than double from FY 2025, with a corresponding increase in revenue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news bri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL96fJJG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619949111","title":"bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic Cypath® Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2619949111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619949111?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:00","pubTimestamp":1773403202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nTUA3FS88B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAFW","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618930334","title":"BioAffinity Technologies initiates clinical study for CyPath Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2618930334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618930334?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:55","pubTimestamp":1773143756,"startTime":"0","endTime":"0","summary":"BioAffinity Technologies (BIAF) announced initiation of the company’s planned large-scale, longitudinal clinical study for CyPath Lung, its noninva...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-initiates-clinical-study-for-cypath-lung-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-initiates-clinical-study-for-cypath-lung-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618937687","title":"bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive Cypath® Lung Cancer Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937687?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:47","pubTimestamp":1773143220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA6YQ8KT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAFW","BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617589616","title":"bioAffinity Technologies directors Robert Anderson and Roby Joyce to step down at April 30 annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2617589616","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617589616?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:31","pubTimestamp":1772832713,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies said directors Robert Anderson and Roby Joyce will not stand for re-election when their terms end at the annual meeting scheduled for April 30, 2026. The company said their decisions were not due to any disagreements over its operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL6yYZdf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616364323","title":"bioAffinity Technologies reports positive findings for asthma therapy-matching sputum diagnostic platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2616364323","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616364323?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:30","pubTimestamp":1772544649,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. reported new research findings on its diagnostic platform’s ability to identify antibody drug receptors in sputum, including receptors for dupilumab and benralizumab, with the aim of supporting therapy selection and monitoring in asthma and chronic obstructive pulmonary disease. The data were presented in a scientific poster titled “Sputum as a Diagnostic Tool for the Treatment of Asthma” at the American Academy of Allergy, Asthma and Immunology 2026 annual meeting on March 1 in Philadelphia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on March 03, 2026, and is solely responsible for the info","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDLbKct7s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614080142","title":"BRIEF-Bioaffinity Announces Validation Study For Lung Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080142","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614080142?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:43","pubTimestamp":1772027014,"startTime":"0","endTime":"0","summary":"BRIEF-Bioaffinity Announces Validation Study For Lung Cancer TestFeb 25 (Reuters) - bioAffinity Technologies Inc BIAF.O:BIOAFFINITY TECHNOLOGIES ANNOUNCES VALIDATION STUDY WITH BROOKE ARMY MEDICAL CEN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA5NNMTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAFW","BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614870460","title":"bioAffinity Technologies Partners With Brooke Army Medical Center on CyPath Lung Validation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2614870460","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614870460?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:31","pubTimestamp":1772026289,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. has launched a validation study with Brooke Army Medical Center to assess the use of its CyPath Lung test on sputum samples collected via tracheal and bronchial suctioning. The study is expected to enroll about 30 to 50 patients, with results anticipated by mid-2026, and could broaden sample collection options to support earlier lung cancer detection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on February 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL67HXS4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614087033","title":"bioAffinity Technologies Announces Validation Study With Brooke Army Medical Center to Expand SAMPLE Collection Options for the Cypath® Lung Noninvasive Early Detection Lung Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2614087033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614087033?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:30","pubTimestamp":1772026204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA5NNMTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BIAFW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612289311","title":"bioAffinity Technologies Highlights CyPath Lung Case Study Supporting Noninvasive Lung Cancer Surveillance","url":"https://stock-news.laohu8.com/highlight/detail?id=2612289311","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612289311?lang=en_us&edition=fundamental","pubTime":"2026-02-20 00:00","pubTimestamp":1771516818,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. announced a new clinical case study describing use of its CyPath Lung noninvasive diagnostic test to help guide management of a 79-year-old patient with a suspicious lung nodule identified on low-dose CT screening. According to the company, the CyPath Lung result was negative and supported a surveillance strategy rather than biopsy; a repeat CT scan later showed resolution of the finding with no pulmonary nodules. The company released the case study with the announcement, indicating the results have already been presented in the published report.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLbDLHYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioaffinitytech.com;ir.bioaffinitytech.com","stockEarnings":[{"period":"1week","weight":-0.2203},{"period":"1month","weight":-0.4383},{"period":"3month","weight":0.6519},{"period":"6month","weight":-0.1585},{"period":"1year","weight":-0.8548},{"period":"ytd","weight":0.8898}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.125018},{"month":2,"riseRate":0.25,"avgChangeRate":-0.070787},{"month":3,"riseRate":0.5,"avgChangeRate":0.528916},{"month":4,"riseRate":0.75,"avgChangeRate":0.158638},{"month":5,"riseRate":0,"avgChangeRate":-0.162067},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.024762},{"month":7,"riseRate":0.666667,"avgChangeRate":0.072762},{"month":8,"riseRate":0,"avgChangeRate":-0.216971},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.17769},{"month":10,"riseRate":0.25,"avgChangeRate":-0.105345},{"month":11,"riseRate":0.25,"avgChangeRate":-0.068737},{"month":12,"riseRate":0,"avgChangeRate":-0.246482}],"exchange":"NASDAQ","name":"bioAffinity Technologies, Inc.","nameEN":"bioAffinity Technologies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"bioAffinity Technologies, Inc.,BIAF,bioAffinity Technologies, Inc.股票,bioAffinity Technologies, Inc.股票老虎,bioAffinity Technologies, Inc.股票老虎国际,bioAffinity Technologies, Inc.行情,bioAffinity Technologies, Inc.股票行情,bioAffinity Technologies, Inc.股价,bioAffinity Technologies, Inc.股市,bioAffinity Technologies, Inc.股票价格,bioAffinity Technologies, Inc.股票交易,bioAffinity Technologies, Inc.股票购买,bioAffinity Technologies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction